Arrowpoint Investment Partners Singapore Pte. Ltd. Purchases Shares of 19,202 AxoGen, Inc. $AXGN

Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 19,202 shares of the medical equipment provider’s stock, valued at approximately $628,000.

Several other large investors also recently modified their holdings of AXGN. Aquatic Capital Management LLC grew its stake in AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 1,269 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in AxoGen by 189.9% during the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 3,327 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of AxoGen during the third quarter worth approximately $64,000. State of Wyoming bought a new stake in shares of AxoGen during the second quarter worth approximately $69,000. Finally, Torren Management LLC acquired a new position in shares of AxoGen in the fourth quarter valued at approximately $88,000. 80.29% of the stock is owned by institutional investors.

AxoGen Trading Up 4.3%

AXGN opened at $42.39 on Friday. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -66.23 and a beta of 1.12. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. AxoGen, Inc. has a twelve month low of $9.22 and a twelve month high of $45.83. The company has a 50-day simple moving average of $38.15 and a 200 day simple moving average of $33.89.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to analyst estimates of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. Analysts predict that AxoGen, Inc. will post -0.3 EPS for the current fiscal year.

Insiders Place Their Bets

In other AxoGen news, Director John Johnson sold 11,050 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the sale, the director owned 11,050 shares of the company’s stock, valued at approximately $478,023. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kathy Johnson Weiler sold 16,344 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $44.09, for a total value of $720,606.96. Following the sale, the director owned 16,344 shares of the company’s stock, valued at approximately $720,606.96. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 34,262 shares of company stock valued at $1,440,250 over the last ninety days. Company insiders own 2.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Canaccord Genuity Group lifted their price target on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Citizens Jmp increased their price objective on AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research report on Wednesday, April 29th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research note on Friday, May 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of AxoGen in a research report on Wednesday, April 29th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.50.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.